A Research Program on Advancing Biomedical Glycoproteomics

Information

  • Research Project
  • 10226014
  • ApplicationId
    10226014
  • Core Project Number
    R35GM128926
  • Full Project Number
    5R35GM128926-04
  • Serial Number
    128926
  • FOA Number
    PAR-17-190
  • Sub Project Id
  • Project Start Date
    8/5/2018 - 6 years ago
  • Project End Date
    6/30/2023 - a year ago
  • Program Officer Name
    KREPKIY, DMITRIY
  • Budget Start Date
    7/1/2021 - 3 years ago
  • Budget End Date
    6/30/2022 - 2 years ago
  • Fiscal Year
    2021
  • Support Year
    04
  • Suffix
  • Award Notice Date
    8/9/2021 - 3 years ago

A Research Program on Advancing Biomedical Glycoproteomics

PROJECT SUMMARY / ABSTRACT The biomedical relevance of disease-related alterations in protein glycosylation has been recognized for some time. However, significant challenges remain in translating these observations into robust disease biomarkers, and in establishing a detailed molecular understanding of how altered protein glycosylation affects a diverse variety of biomolecular interactions and protein structure / function interplays. Because protein glycosylation is the end result of complex non-template-driven biosynthetic processes, a protein glycoform profile is exquisitely sensitive to metabolic irregularities, including those that accompany disease. For these reasons, the detailed molecular characterization of protein glycosylation is of great biomedical interest in the context of disease biomarker discovery, and for the purpose of relating disease-induced alterations of protein glycosylation to protein function. Essential to such endeavors are powerful analytical techniques that can determine the compositions and structures of protein-linked glycans and their sites of protein attachment in complex and heterogeneous mixtures. This application to the MIRA program requests support of a research program dedicated to the advancement of biomedical glycoproteomics through the development, application, and dissemination of mass spectrometry, tandem mass spectrometry, and ion mobility spectrometry based tools for interrogating the glycoproteome and determining site-specific protein glycoforms. The goals of this program are consonant with current NIH priorities, including the recent calls for increased investment in early stage development of new technologies for biomedical research and ongoing initiatives to catalyze advancements in glycoscience. The new technologies that will result from this work will be generalizable and thus applicable to the elucidation of site-specific protein glycoform patterns in an eclectic array of biomedically-relevant contexts.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    R35
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
    250000
  • Indirect Cost Amount
    118696
  • Total Cost
    368696
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    859
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NIGMS:368696\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZGM1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF NEBRASKA LINCOLN
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    555456995
  • Organization City
    LINCOLN
  • Organization State
    NE
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    685032427
  • Organization District
    UNITED STATES